CA
PTCT icon

Crewe Advisors’s PTC Therapeutics PTCT Stock Holding History

Crewe Advisors’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-119
Closed -$5.76K – 982
2023
Q1 		$5.76K Hold
119
– – ﹤0.01% 619
2022
Q4 		$4.54K Hold
119
– – ﹤0.01% 691
2022
Q3 		$6K Hold
119
– – ﹤0.01% 815
2022
Q2 		$5K Buy
+119
New +$4.17K ﹤0.01% 772

Other funds holding PTCT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Crewe Advisors's PTCT Position: Q2 2023 in Review

Crewe Advisors sold out of PTC Therapeutics (PTCT) in Q2 2023, closing a stake of 119 shares — an estimated $5.76K sold.

Crewe Advisors first reported a position in PTCT in Q2 2022 and held it in 4 quarters. The position peaked at $6K in Q3 2022. 204 funds tracked by Wall St. Rank hold PTCT as of Q2 2023.

  • Crewe Advisors reported no remaining PTC Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Crewe Advisors sold 119 PTC Therapeutics shares in Q2 2023, an estimated $5.76K.
  • Crewe Advisors first reported a position in PTC Therapeutics in Q2 2022 and held it in 4 quarters.
  • Crewe Advisors's PTC Therapeutics position peaked at $6K in Q3 2022.
  • 204 funds tracked by Wall St. Rank held PTC Therapeutics as of Q2 2023.

Based on Crewe Advisors's 13F filing for Q2 2023, filed 28 Jul 2023.